{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T04:14:35Z","timestamp":1789704875386,"version":"4.0.1"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,9]]},"DOI":"10.7759\/cureus.103304","type":"journal-article","created":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T21:57:34Z","timestamp":1770674254000},"source":"Crossref","is-referenced-by-count":1,"title":["Potential Synergistic Roles of Ketogenic Diet and Stem Cell Therapy in Parkinson's Disease: A Narrative Review"],"prefix":"10.7759","author":[{"given":"Princy","family":"Sindurakar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasavi  R","family":"Gorantla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dovenia","family":"Ponnoth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Parkinson\u2019s disease: etiology, neuropathology, and pathogenesis","author":"Kouli A","year":"2018","unstructured":"Kouli A, Torsney KM, Kuan WL. Parkinson\u2019s disease: etiology, neuropathology, and pathogenesis. Parkinson\u2019s Disease: Pathogenesis and Clinical Aspects. Stoker TB, Greenland JC (ed): Codon Publications, Brisbane, AU; 2018."},{"key":"ref2","article-title":"Parkinson disease","author":"Zafar S","year":"2025","unstructured":"Zafar S, Lui F, Yaddanapudi SS. Parkinson disease. StatPearls. StatPearls Publishing, Treasure Island, FL; 2025."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3233\/JPD-181493","article-title":"The search for environmental causes of Parkinson\u2019s disease: moving forward","volume":"8","author":"Chen H","year":"2018","unstructured":"Chen H, Ritz B. The search for environmental causes of Parkinson\u2019s disease: moving forward. J Parkinsons Dis. 2018, 8:S9-17. 10.3233\/JPD-181493","journal-title":"J Parkinsons Dis"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000037538","article-title":"Evaluation of substantia nigra morphology in Parkinson\u2019s disease","volume":"103","author":"Durmaz \u00c7elik N","year":"2024","unstructured":"Durmaz \u00c7elik N, Yaman Kula A, Toprak U, Sayl\u0131soy S, Topal A, \u00d6zkan S. Evaluation of substantia nigra morphology in Parkinson\u2019s disease. Medicine (Baltimore). 2024, 103:e37538. 10.1097\/MD.0000000000037538","journal-title":"Medicine (Baltimore)"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(04)00740-9","article-title":"Challenges in Parkinson\u2019s disease: restoration of the nigrostriatal dopamine system is not enough","volume":"3","author":"Lang AE","year":"2004","unstructured":"Lang AE, Obeso JA. Challenges in Parkinson\u2019s disease: restoration of the nigrostriatal dopamine system is not enough. Lancet Neurol. 2004, 3:309-16. 10.1016\/S1474-4422(04)00740-9","journal-title":"Lancet Neurol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-510X(97)00100-7","article-title":"Correlation between neuromorphometry in the substantia nigra and clinical features in Parkinson\u2019s disease using disector counts","volume":"151","author":"Ma SY","year":"1997","unstructured":"Ma SY, R\u00f6ytt\u00e4 M, Rinne JO, Collan Y, Rinne UK. Correlation between neuromorphometry in the substantia nigra and clinical features in Parkinson\u2019s disease using disector counts. J Neurol Sci. 1997, 151:83-7. 10.1016\/S0022-510X(97)00100-7","journal-title":"J Neurol Sci"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2018.00455","article-title":"On cell loss and selective vulnerability of neuronal populations in Parkinson\u2019s disease","volume":"9","author":"Gigu\u00e8re N","year":"2018","unstructured":"Gigu\u00e8re N, Burke Nanni S, Trudeau LE. On cell loss and selective vulnerability of neuronal populations in Parkinson\u2019s disease. Front Neurol. 2018, 9:455. 10.3389\/fneur.2018.00455","journal-title":"Front Neurol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awt192","article-title":"Disease duration and the integrity of the nigrostriatal system in Parkinson's disease","volume":"136","author":"Kordower JH","year":"2013","unstructured":"Kordower JH, Olanow CW, Dodiya HB, et al.. Disease duration and the integrity of the nigrostriatal system in Parkinson's disease. Brain. 2013, 136:2419-31. 10.1093\/brain\/awt192","journal-title":"Brain"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.5692\/clinicalneurol.48.981","article-title":"[Lewy body formation in Parkinson's disease: neurodegeneration or neuroprotection?]","volume":"48","author":"Wakabayashi K","year":"2008","unstructured":"Wakabayashi K. [Lewy body formation in Parkinson's disease: neurodegeneration or neuroprotection?]. Rinsho Shinkeigaku. 2008, 48:981-3. 10.5692\/clinicalneurol.48.981","journal-title":"Rinsho Shinkeigaku"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-023-00622-7","article-title":"Neuropathology of incidental Lewy body & prodromal Parkinson's disease","volume":"18","author":"Koeglsperger T","year":"2023","unstructured":"Koeglsperger T, Rumpf SL, Schlie\u00dfer P, et al.. Neuropathology of incidental Lewy body & prodromal Parkinson's disease. Mol Neurodegener. 2023, 18:32. 10.1186\/s13024-023-00622-7","journal-title":"Mol Neurodegener"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.2741\/2973","article-title":"Proteomic identification of novel proteins associated with Lewy bodies","volume":"13","author":"Xia Q","year":"2008","unstructured":"Xia Q, Liao L, Cheng D, et al.. Proteomic identification of novel proteins associated with Lewy bodies. Front Biosci. 2008, 13:3850-6. 10.2741\/2973","journal-title":"Front Biosci"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/S0197-4580(02)00065-9","article-title":"Staging of brain pathology related to sporadic Parkinson\u2019s disease","volume":"24","author":"Braak H","year":"2003","unstructured":"Braak H, Del Tredici K, R\u00fcb U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson\u2019s disease. Neurobiol Aging. 2003, 24:197-211. 10.1016\/S0197-4580(02)00065-9","journal-title":"Neurobiol Aging"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-023-00676-7","article-title":"Mitochondrial dysfunction in Parkinson's disease - a key disease hallmark with therapeutic potential","volume":"18","author":"Henrich MT","year":"2023","unstructured":"Henrich MT, Oertel WH, Surmeier DJ, Geibl FF. Mitochondrial dysfunction in Parkinson's disease - a key disease hallmark with therapeutic potential. Mol Neurodegener. 2023, 18:83. 10.1186\/s13024-023-00676-7","journal-title":"Mol Neurodegener"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.mito.2011.05.013","article-title":"The antioxidant Trolox helps recovery from the familial Parkinson\u2019s disease-specific mitochondrial deficits caused by PINK1- and DJ-1-deficiency in dopaminergic neuronal cells","volume":"11","author":"Shim JH","year":"2011","unstructured":"Shim JH, Yoon SH, Kim KH, et al.. The antioxidant Trolox helps recovery from the familial Parkinson\u2019s disease-specific mitochondrial deficits caused by PINK1- and DJ-1-deficiency in dopaminergic neuronal cells. Mitochondrion. 2011, 11:707-15. 10.1016\/j.mito.2011.05.013","journal-title":"Mitochondrion"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.1990.tb02325.x","article-title":"Mitochondrial complex I deficiency in Parkinson's disease","volume":"54","author":"Schapira AH","year":"1990","unstructured":"Schapira AH, Cooper JM, Dexter D, Clark JB, Jenner P, Marsden CD. Mitochondrial complex I deficiency in Parkinson's disease. J Neurochem. 1990, 54:823-7. 10.1111\/j.1471-4159.1990.tb02325.x","journal-title":"J Neurochem"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3233\/JPD-2011-11023","article-title":"MPTP mouse models of Parkinson's disease: an update","volume":"1","author":"Meredith GE","year":"2011","unstructured":"Meredith GE, Rademacher DJ. MPTP mouse models of Parkinson's disease: an update. J Parkinsons Dis. 2011, 1:19-33. 10.3233\/JPD-2011-11023","journal-title":"J Parkinsons Dis"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(85)90146-8","article-title":"Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine","volume":"36","author":"Nicklas WJ","year":"1985","unstructured":"Nicklas WJ, Vyas I, Heikkila RE. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. Life Sci. 1985, 36:2503-8. 10.1016\/0024-3205(85)90146-8","journal-title":"Life Sci"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.2174\/1871527315666160920160512","article-title":"An overview on the role of \u03b1-synuclein in experimental models of Parkinson\u2019s disease from pathogenesis to therapeutics","volume":"15","author":"Javed H","year":"2016","unstructured":"Javed H, Kamal MA, Ojha S. An overview on the role of \u03b1-synuclein in experimental models of Parkinson\u2019s disease from pathogenesis to therapeutics. CNS Neurol Disord Drug Targets. 2016, 15:1240-52. 10.2174\/1871527315666160920160512","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.1157-19.2019","article-title":"Pleiotropic mitochondria: the influence of mitochondria on neuronal development and disease","volume":"39","author":"Rangaraju V","year":"2019","unstructured":"Rangaraju V, Lewis TL Jr, Hirabayashi Y, et al.. Pleiotropic mitochondria: the influence of mitochondria on neuronal development and disease. J Neurosci. 2019, 39:8200-8. 10.1523\/JNEUROSCI.1157-19.2019","journal-title":"J Neurosci"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.cub.2015.07.050","article-title":"Elevated mitochondrial bioenergetics and axonal arborization size are key contributors to the vulnerability of dopamine neurons","volume":"25","author":"Pacelli C","year":"2015","unstructured":"Pacelli C, Gigu\u00e8re N, Bourque MJ, L\u00e9vesque M, Slack RS, Trudeau L\u00c9. Elevated mitochondrial bioenergetics and axonal arborization size are key contributors to the vulnerability of dopamine neurons. Curr Biol. 2015, 25:2349-60. 10.1016\/j.cub.2015.07.050","journal-title":"Curr Biol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1038\/nn.3717","article-title":"Mitochondrial oxidant stress in locus coeruleus is regulated by activity and nitric oxide synthase","volume":"17","author":"Sanchez-Padilla J","year":"2014","unstructured":"Sanchez-Padilla J, Guzman JN, Ilijic E, et al.. Mitochondrial oxidant stress in locus coeruleus is regulated by activity and nitric oxide synthase. Nat Neurosci. 2014, 17:832-40. 10.1038\/nn.3717","journal-title":"Nat Neurosci"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1038\/nrn1868","article-title":"Expanding insights of mitochondrial dysfunction in Parkinson's disease","volume":"7","author":"Abou-Sleiman PM","year":"2006","unstructured":"Abou-Sleiman PM, Muqit MM, Wood NW. Expanding insights of mitochondrial dysfunction in Parkinson's disease. Nat Rev Neurosci. 2006, 7:207-19. 10.1038\/nrn1868","journal-title":"Nat Rev Neurosci"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-023-02641-6","article-title":"Parkinson's disease therapy: what lies ahead?","volume":"130","author":"Wolff A","year":"2023","unstructured":"Wolff A, Schumacher NU, P\u00fcrner D, et al.. Parkinson's disease therapy: what lies ahead?. J Neural Transm (Vienna). 2023, 130:793-820. 10.1007\/s00702-023-02641-6","journal-title":"J Neural Transm (Vienna)"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3390\/nu14214472","article-title":"The role of diet and dietary patterns in Parkinson\u2019s disease","volume":"14","author":"Knight E","year":"2022","unstructured":"Knight E, Geetha T, Burnett D, Babu JR. The role of diet and dietary patterns in Parkinson\u2019s disease. Nutrients. 2022, 14:4472. 10.3390\/nu14214472","journal-title":"Nutrients"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2023.1246998","article-title":"Regulation of adult stem cell function by ketone bodies","volume":"11","author":"Andersen OE","year":"2023","unstructured":"Andersen OE, Poulsen JV, Farup J, de Morree A. Regulation of adult stem cell function by ketone bodies. Front Cell Dev Biol. 2023, 11:1246998. 10.3389\/fcell.2023.1246998","journal-title":"Front Cell Dev Biol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2012.04.002","article-title":"Short-term calorie restriction enhances skeletal muscle stem cell function","volume":"10","author":"Cerletti M","year":"2012","unstructured":"Cerletti M, Jang YC, Finley LW, Haigis MC, Wagers AJ. Short-term calorie restriction enhances skeletal muscle stem cell function. Cell Stem Cell. 2012, 10:515-9. 10.1016\/j.stem.2012.04.002","journal-title":"Cell Stem Cell"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20151100","article-title":"Dietary restriction improves repopulation but impairs lymphoid differentiation capacity of hematopoietic stem cells in early aging","volume":"213","author":"Tang D","year":"2016","unstructured":"Tang D, Tao S, Chen Z, et al.. Dietary restriction improves repopulation but impairs lymphoid differentiation capacity of hematopoietic stem cells in early aging. J Exp Med. 2016, 213:535-53. 10.1084\/jem.20151100","journal-title":"J Exp Med"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a026096","article-title":"Genome stability requires p53","volume":"6","author":"Eischen CM","year":"2016","unstructured":"Eischen CM. Genome stability requires p53. Cold Spring Harb Perspect Med. 2016, 6:a026096. 10.1101\/cshperspect.a026096","journal-title":"Cold Spring Harb Perspect Med"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2018.06.016","article-title":"Ketogenic diet attenuates oxidative stress and inflammation after spinal cord injury by activating Nrf2 and suppressing the NF-\u03baB signaling pathways","volume":"683","author":"Lu Y","year":"2018","unstructured":"Lu Y, Yang YY, Zhou MW, Liu N, Xing HY, Liu XX, Li F. Ketogenic diet attenuates oxidative stress and inflammation after spinal cord injury by activating Nrf2 and suppressing the NF-\u03baB signaling pathways. Neurosci Lett. 2018, 683:13-8. 10.1016\/j.neulet.2018.06.016","journal-title":"Neurosci Lett"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3804","article-title":"The ketone metabolite \u03b2-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease","volume":"21","author":"Youm YH","year":"2015","unstructured":"Youm YH, Nguyen KY, Grant RW, et al.. The ketone metabolite \u03b2-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease. Nat Med. 2015, 21:263-9. 10.1038\/nm.3804","journal-title":"Nat Med"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.3390\/nu13051654","article-title":"The potential health benefits of the ketogenic diet: a narrative review","volume":"13","author":"Dowis K","year":"2021","unstructured":"Dowis K, Banga S. The potential health benefits of the ketogenic diet: a narrative review. Nutrients. 2021, 13:1654. 10.3390\/nu13051654","journal-title":"Nutrients"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2016.12.022","article-title":"Multi-dimensional roles of ketone bodies in fuel metabolism, signaling, and therapeutics","volume":"25","author":"Puchalska P","year":"2017","unstructured":"Puchalska P, Crawford PA. Multi-dimensional roles of ketone bodies in fuel metabolism, signaling, and therapeutics. Cell Metab. 2017, 25:262-84. 10.1016\/j.cmet.2016.12.022","journal-title":"Cell Metab"},{"key":"ref33","article-title":"The ketogenic diet: clinical applications, evidence-based indications, and implementation","author":"Daley SF","year":"2025","unstructured":"Daley SF, Masood W, Annamaraju P, Khan Suheb MZ. The ketogenic diet: clinical applications, evidence-based indications, and implementation. StatPearls. StatPearls Publishing, Treasure Island, FL; 2025."},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2008.01821.x","article-title":"History of the ketogenic diet","volume":"49","author":"Wheless JW","year":"2008","unstructured":"Wheless JW. History of the ketogenic diet. Epilepsia. 2008, 49:3-5. 10.1111\/j.1528-1167.2008.01821.x","journal-title":"Epilepsia"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1542\/peds.102.6.1358","article-title":"The efficacy of the ketogenic diet\u20141998: a prospective evaluation of intervention in 150 children","volume":"102","author":"Freeman JM","year":"1998","unstructured":"Freeman JM, Vining EP, Pillas DJ, Pyzik PL, Casey JC, Kelly LM. The efficacy of the ketogenic diet\u20141998: a prospective evaluation of intervention in 150 children. Pediatrics. 1998, 102:1358-63. 10.1542\/peds.102.6.1358","journal-title":"Pediatrics"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/j.braindev.2017.03.027","article-title":"Low glycemic index treatment in patients with drug-resistant epilepsy","volume":"39","author":"Kim SH","year":"2017","unstructured":"Kim SH, Kang HC, Lee EJ, Lee JS, Kim HD. Low glycemic index treatment in patients with drug-resistant epilepsy. Brain Dev. 2017, 39:687-92. 10.1016\/j.braindev.2017.03.027","journal-title":"Brain Dev"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.3390\/nu14235003","article-title":"The role of ketogenic diet in the treatment of neurological diseases","volume":"14","author":"Dy\u0144ka D","year":"2022","unstructured":"Dy\u0144ka D, Kowalcze K, Paziewska A. The role of ketogenic diet in the treatment of neurological diseases. Nutrients. 2022, 14:5003. 10.3390\/nu14235003","journal-title":"Nutrients"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1093\/ajcn\/86.2.276","article-title":"Low-carbohydrate nutrition and metabolism","volume":"86","author":"Westman EC","year":"2007","unstructured":"Westman EC, Feinman RD, Mavropoulos JC, et al.. Low-carbohydrate nutrition and metabolism. Am J Clin Nutr. 2007, 86:276-84. 10.1093\/ajcn\/86.2.276","journal-title":"Am J Clin Nutr"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-142-6-200503150-00006","article-title":"Effect of a low-carbohydrate diet on appetite, blood glucose levels, and insulin resistance in obese patients with type 2 diabetes","volume":"142","author":"Boden G","year":"2005","unstructured":"Boden G, Sargrad K, Homko C, Mozzoli M, Stein TP. Effect of a low-carbohydrate diet on appetite, blood glucose levels, and insulin resistance in obese patients with type 2 diabetes. Ann Intern Med. 2005, 142:403-11. 10.7326\/0003-4819-142-6-200503150-00006","journal-title":"Ann Intern Med"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.29245\/2572.942x\/2023\/1.1286","article-title":"Exploring the therapeutic potential of the ketogenic diet on neurological disorders: a comprehensive review","volume":"7","author":"Vallamchelta SK","year":"2023","unstructured":"Vallamchelta SK. Exploring the therapeutic potential of the ketogenic diet on neurological disorders: a comprehensive review. J Neurol Neuromedicine. 2023, 7:1-8. 10.29245\/2572.942x\/2023\/1.1286","journal-title":"J Neurol Neuromedicine"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0511154103","article-title":"Increased production of reactive oxygen species in hyperglycemic conditions requires dynamic change of mitochondrial morphology","volume":"103","author":"Yu T","year":"2006","unstructured":"Yu T, Robotham JL, Yoon Y. Increased production of reactive oxygen species in hyperglycemic conditions requires dynamic change of mitochondrial morphology. Proc Natl Acad Sci U S A. 2006, 103:2653-8. 10.1073\/pnas.0511154103","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26513","article-title":"Dementia in Parkinson's disease is associated with enhanced mitochondrial complex I deficiency","volume":"31","author":"Gatt AP","year":"2016","unstructured":"Gatt AP, Duncan OF, Attems J, Francis PT, Ballard CG, Bateman JM. Dementia in Parkinson's disease is associated with enhanced mitochondrial complex I deficiency. Mov Disord. 2016, 31:352-9. 10.1002\/mds.26513","journal-title":"Mov Disord"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1016\/j.pneurobio.2013.04.004","article-title":"Mitochondrial dysfunction and oxidative stress in Parkinson's disease","volume":"106-7","author":"Subramaniam SR","year":"2013","unstructured":"Subramaniam SR, Chesselet MF. Mitochondrial dysfunction and oxidative stress in Parkinson's disease. Prog Neurobiol. 2013, 106-7:17-32. 10.1016\/j.pneurobio.2013.04.004","journal-title":"Prog Neurobiol"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.268","article-title":"Ketogenic diet protects MPTP-induced mouse model of Parkinson's disease via altering gut microbiota and metabolites","volume":"4","author":"Jiang Z","year":"2023","unstructured":"Jiang Z, Wang X, Zhang H, Yin J, Zhao P, Yin Q, Wang Z. Ketogenic diet protects MPTP-induced mouse model of Parkinson's disease via altering gut microbiota and metabolites. MedComm (2020). 2023, 4:e268. 10.1002\/mco2.268","journal-title":"MedComm (2020)"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1177\/0271678X15610584","article-title":"Ketogenic diet decreases oxidative stress and improves mitochondrial respiratory complex activity","volume":"36","author":"Greco T","year":"2016","unstructured":"Greco T, Glenn TC, Hovda DA, Prins ML. Ketogenic diet decreases oxidative stress and improves mitochondrial respiratory complex activity. J Cereb Blood Flow Metab. 2016, 36:1603-13. 10.1177\/0271678X15610584","journal-title":"J Cereb Blood Flow Metab"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1111\/jnc.12646","article-title":"The ketogenic diet component decanoic acid increases mitochondrial citrate synthase and complex I activity in neuronal cells","volume":"129","author":"Hughes SD","year":"2014","unstructured":"Hughes SD, Kanabus M, Anderson G, et al.. The ketogenic diet component decanoic acid increases mitochondrial citrate synthase and complex I activity in neuronal cells. J Neurochem. 2014, 129:426-33. 10.1111\/jnc.12646","journal-title":"J Neurochem"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20081850","article-title":"Dietary macronutrient management to treat mitochondrial dysfunction in Parkinson\u2019s disease","volume":"20","author":"Bajracharya R","year":"2019","unstructured":"Bajracharya R, Youngson NA, Ballard JW. Dietary macronutrient management to treat mitochondrial dysfunction in Parkinson\u2019s disease. Int J Mol Sci. 2019, 20:1850. 10.3390\/ijms20081850","journal-title":"Int J Mol Sci"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-05672-9","article-title":"Alpha-synuclein in Parkinson's disease and other synucleinopathies: from overt neurodegeneration back to early synaptic dysfunction","volume":"14","author":"Calabresi P","year":"2023","unstructured":"Calabresi P, Mechelli A, Natale G, Volpicelli-Daley L, Di Lazzaro G, Ghiglieri V. Alpha-synuclein in Parkinson's disease and other synucleinopathies: from overt neurodegeneration back to early synaptic dysfunction. Cell Death Dis. 2023, 14:176. 10.1038\/s41419-023-05672-9","journal-title":"Cell Death Dis"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.3164\/jcbn.22-73","article-title":"High-fat diet causes mitochondrial damage and downregulation of mitofusin-2 and optic atrophy-1 in multiple organs","volume":"73","author":"Zheng P","year":"2023","unstructured":"Zheng P, Ma W, Gu Y, et al.. High-fat diet causes mitochondrial damage and downregulation of mitofusin-2 and optic atrophy-1 in multiple organs. J Clin Biochem Nutr. 2023, 73:61-76. 10.3164\/jcbn.22-73","journal-title":"J Clin Biochem Nutr"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-022-00684-6","article-title":"Inflammation and immune dysfunction in Parkinson disease","volume":"22","author":"Tansey MG","year":"2022","unstructured":"Tansey MG, Wallings RL, Houser MC, Herrick MK, Keating CE, Joers V. Inflammation and immune dysfunction in Parkinson disease. Nat Rev Immunol. 2022, 22:657-73. 10.1038\/s41577-022-00684-6","journal-title":"Nat Rev Immunol"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2020.106454","article-title":"Ketogenic diet and neuroinflammation","volume":"167","author":"Koh S","year":"2020","unstructured":"Koh S, Dupuis N, Auvin S. Ketogenic diet and neuroinflammation. Epilepsy Res. 2020, 167:106454. 10.1016\/j.eplepsyres.2020.106454","journal-title":"Epilepsy Res"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2010.09.002","article-title":"Metabolic control of vesicular glutamate transport and release","volume":"68","author":"Juge N","year":"2010","unstructured":"Juge N, Gray JA, Omote H, et al.. Metabolic control of vesicular glutamate transport and release. Neuron. 2010, 68:99-112. 10.1016\/j.neuron.2010.09.002","journal-title":"Neuron"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(09)70062-6","article-title":"Neuroinflammation in Parkinson\u2019s disease: a target for neuroprotection?","volume":"8","author":"Hirsch EC","year":"2009","unstructured":"Hirsch EC, Hunot S. Neuroinflammation in Parkinson\u2019s disease: a target for neuroprotection?. Lancet Neurol. 2009, 8:382-97. 10.1016\/S1474-4422(09)70062-6","journal-title":"Lancet Neurol"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2005.07.005","article-title":"Alterations of T-lymphocyte populations in Parkinson disease","volume":"11","author":"Baba Y","year":"2005","unstructured":"Baba Y, Kuroiwa A, Uitti RJ, Wszolek ZK, Yamada T. Alterations of T-lymphocyte populations in Parkinson disease. Parkinsonism Relat Disord. 2005, 11:493-8. 10.1016\/j.parkreldis.2005.07.005","journal-title":"Parkinsonism Relat Disord"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3940(94)90508-8","article-title":"Interleukin-1\u03b2, interleukin-6, epidermal growth factor and transforming growth factor-\u03b1 are elevated in the brain from parkinsonian patients","volume":"180","author":"Mogi M","year":"1994","unstructured":"Mogi M, Harada M, Kondo T, Riederer P, Inagaki H, Minami M, Nagatsu T. Interleukin-1\u03b2, interleukin-6, epidermal growth factor and transforming growth factor-\u03b1 are elevated in the brain from parkinsonian patients. Neurosci Lett. 1994, 180:147-50. 10.1016\/0304-3940(94)90508-8","journal-title":"Neurosci Lett"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abo7639","article-title":"Ketogenic diet uncovers differential metabolic plasticity of brain cells","volume":"8","author":"D\u00fcking T","year":"2022","unstructured":"D\u00fcking T, Spieth L, Berghoff SA, et al.. Ketogenic diet uncovers differential metabolic plasticity of brain cells. Sci Adv. 2022, 8:eabo7639. 10.1126\/sciadv.abo7639","journal-title":"Sci Adv"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2018-320157","article-title":"Clinical implications of early caudate dysfunction in Parkinson's disease","volume":"90","author":"Pasquini J","year":"2019","unstructured":"Pasquini J, Durcan R, Wiblin L, et al.. Clinical implications of early caudate dysfunction in Parkinson's disease. J Neurol Neurosurg Psychiatry. 2019, 90:1098-104. 10.1136\/jnnp-2018-320157","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.15586\/codonpublications.parkinsonsdisease.2018.ch9","article-title":"Stem cell treatments for Parkinson\u2019s disease","author":"Stoker TB","year":"2018","unstructured":"Stoker TB. Stem cell treatments for Parkinson\u2019s disease. Parkinson\u2019s Disease: Pathogenesis and Clinical Aspects. Stoker TB, Greenland JC (ed): Codon Publications, Brisbane, AU; 2018. 10.15586\/codonpublications.parkinsonsdisease.2018.ch9"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2014.09.017","article-title":"Human ESC-derived dopamine neurons show similar preclinical efficacy and potency to fetal neurons when grafted in a rat model of Parkinson's disease","volume":"15","author":"Grealish S","year":"2014","unstructured":"Grealish S, Diguet E, Kirkeby A, et al.. Human ESC-derived dopamine neurons show similar preclinical efficacy and potency to fetal neurons when grafted in a rat model of Parkinson's disease. Cell Stem Cell. 2014, 15:653-65. 10.1016\/j.stem.2014.09.017","journal-title":"Cell Stem Cell"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.8940-21","article-title":"Recent advances in drug therapy for Parkinson\u2019s disease","volume":"62","author":"Murakami H","year":"2023","unstructured":"Murakami H, Shiraishi T, Umehara T, Omoto S, Iguchi Y. Recent advances in drug therapy for Parkinson\u2019s disease. Intern Med. 2023, 62:33-42. 10.2169\/internalmedicine.8940-21","journal-title":"Intern Med"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1192\/j.eurpsy.2022.1765","article-title":"Psychotic symptoms in the context of levodopa treatment in Parkinson\u2019s disease: clinical feature or iatrogenesis?","volume":"65","author":"Costa ML","year":"2022","unstructured":"Costa ML, Cerame A. Psychotic symptoms in the context of levodopa treatment in Parkinson\u2019s disease: clinical feature or iatrogenesis?. Eur Psychiatry. 2022, 65:S686. 10.1192\/j.eurpsy.2022.1765","journal-title":"Eur Psychiatry"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1038\/jcbfm.2015.32","article-title":"Striatal blood-brain barrier permeability in Parkinson's disease","volume":"35","author":"Gray MT","year":"2015","unstructured":"Gray MT, Woulfe JM. Striatal blood-brain barrier permeability in Parkinson's disease. J Cereb Blood Flow Metab. 2015, 35:747-50. 10.1038\/jcbfm.2015.32","journal-title":"J Cereb Blood Flow Metab"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2010.09.043","article-title":"Pericytes control key neurovascular functions and neuronal phenotype in the adult brain and during brain aging","volume":"68","author":"Bell RD","year":"2010","unstructured":"Bell RD, Winkler EA, Sagare AP, Singh I, LaRue B, Deane R, Zlokovic BV. Pericytes control key neurovascular functions and neuronal phenotype in the adult brain and during brain aging. Neuron. 2010, 68:409-27. 10.1016\/j.neuron.2010.09.043","journal-title":"Neuron"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awr165","article-title":"Vascular endothelial growth factor is upregulated by L-dopa in the parkinsonian brain: implications for the development of dyskinesia","volume":"134","author":"Ohlin KE","year":"2011","unstructured":"Ohlin KE, Francardo V, Lindgren HS, et al.. Vascular endothelial growth factor is upregulated by L-dopa in the parkinsonian brain: implications for the development of dyskinesia. Brain. 2011, 134:2339-57. 10.1093\/brain\/awr165","journal-title":"Brain"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2020.593026","article-title":"Blood-brain barrier leakage is increased in Parkinson\u2019s disease","volume":"11","author":"Al-Bachari S","year":"2020","unstructured":"Al-Bachari S, Naish JH, Parker GJ, Emsley HC, Parkes LM. Blood-brain barrier leakage is increased in Parkinson\u2019s disease. Front Physiol. 2020, 11:593026. 10.3389\/fphys.2020.593026","journal-title":"Front Physiol"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2015.123","article-title":"Cell-based therapies for Parkinson disease\u2014past insights and future potential","volume":"11","author":"Barker RA","year":"2015","unstructured":"Barker RA, Drouin-Ouellet J, Parmar M. Cell-based therapies for Parkinson disease\u2014past insights and future potential. Nat Rev Neurol. 2015, 11:492-503. 10.1038\/nrneurol.2015.123","journal-title":"Nat Rev Neurol"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.3390\/cells10092319","article-title":"Induced pluripotent stem cells (iPSCs)-roles in regenerative therapies, disease modelling and drug screening","volume":"10","author":"Aboul-Soud MA","year":"2021","unstructured":"Aboul-Soud MA, Alzahrani AJ, Mahmoud A. Induced pluripotent stem cells (iPSCs)-roles in regenerative therapies, disease modelling and drug screening. Cells. 2021, 10:2319. 10.3390\/cells10092319","journal-title":"Cells"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1590\/1414-431X2024e13482","article-title":"Revealing induced pluripotent stem cells' potential as a better alternative to embryonic stem cells for Parkinson's disease treatment based on single-cell RNA-seq","volume":"57","author":"Zhang S","year":"2024","unstructured":"Zhang S, Jiang X, Yan M, et al.. Revealing induced pluripotent stem cells' potential as a better alternative to embryonic stem cells for Parkinson's disease treatment based on single-cell RNA-seq. Braz J Med Biol Res. 2024, 57:e13482. 10.1590\/1414-431X2024e13482","journal-title":"Braz J Med Biol Res"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-75008-6","article-title":"Elevated caudate connectivity in cognitively normal Parkinson's disease patients","volume":"10","author":"Wright N","year":"2020","unstructured":"Wright N, Alhindi A, Millikin C, et al.. Elevated caudate connectivity in cognitively normal Parkinson's disease patients. Sci Rep. 2020, 10:17978. 10.1038\/s41598-020-75008-6","journal-title":"Sci Rep"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurobiolaging.2017.08.020","article-title":"Distinct brain metabolic patterns separately associated with cognition, motor function, and aging in Parkinson's disease dementia","volume":"60","author":"Ko JH","year":"2017","unstructured":"Ko JH, Katako A, Aljuaid M, et al.. Distinct brain metabolic patterns separately associated with cognition, motor function, and aging in Parkinson's disease dementia. Neurobiol Aging. 2017, 60:81-91. 10.1016\/j.neurobiolaging.2017.08.020","journal-title":"Neurobiol Aging"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1038\/nature17173","article-title":"High-fat diet enhances stemness and tumorigenicity of intestinal progenitors","volume":"531","author":"Beyaz S","year":"2016","unstructured":"Beyaz S, Mana MD, Roper J, et al.. High-fat diet enhances stemness and tumorigenicity of intestinal progenitors. Nature. 2016, 531:53-8. 10.1038\/nature17173","journal-title":"Nature"},{"key":"ref72","article-title":"Levodopa (L-dopa)","author":"Gandhi KR","year":"2023","unstructured":"Gandhi KR, Saadabadi A. Levodopa (L-dopa). StatPearls. StatPearls Publishing, Treasure Island, FL; 2023."},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410440722","article-title":"Levodopa toxicity and apoptosis","volume":"44","author":"Melamed E","year":"1998","unstructured":"Melamed E, Offen D, Shirvan A, Djaldetti R, Barzilai A, Ziv I. Levodopa toxicity and apoptosis. Ann Neurol. 1998, 44:S149-54. 10.1002\/ana.410440722","journal-title":"Ann Neurol"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.1016\/j.nsa.2024.104061","article-title":"Research progress of cell treatment strategy in Parkinson's disease","volume":"3","author":"Peng YL","year":"2024","unstructured":"Peng YL, Chen J, Hu H, Liu W, Liang W, Wang J. Research progress of cell treatment strategy in Parkinson's disease. Neurosci Appl. 2024, 3:104061. 10.1016\/j.nsa.2024.104061","journal-title":"Neurosci Appl"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-024-02176-z","article-title":"Neural stem cells derived from \u03b1-synuclein-knockdown iPS cells alleviate Parkinson's disease","volume":"10","author":"Wang CH","year":"2024","unstructured":"Wang CH, Lin GC, Fu RH, et al.. Neural stem cells derived from \u03b1-synuclein-knockdown iPS cells alleviate Parkinson's disease. Cell Death Discov. 2024, 10:407. 10.1038\/s41420-024-02176-z","journal-title":"Cell Death Discov"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.022438099","article-title":"Embryonic stem cells develop into functional dopaminergic neurons after transplantation in a Parkinson rat model","volume":"99","author":"Bjorklund LM","year":"2002","unstructured":"Bjorklund LM, S\u00e1nchez-Pernaute R, Chung S, et al.. Embryonic stem cells develop into functional dopaminergic neurons after transplantation in a Parkinson rat model. Proc Natl Acad Sci U S A. 2002, 99:2344-9. 10.1073\/pnas.022438099","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-022-00681-2","article-title":"The microbiome-gut-brain axis in Parkinson disease\u2014from basic research to the clinic","volume":"18","author":"Tan AH","year":"2022","unstructured":"Tan AH, Lim SY, Lang AE. The microbiome-gut-brain axis in Parkinson disease\u2014from basic research to the clinic. Nat Rev Neurol. 2022, 18:476-95. 10.1038\/s41582-022-00681-2","journal-title":"Nat Rev Neurol"},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.1101\/gad.346973.120","article-title":"Dietary interventions as regulators of stem cell behavior in homeostasis and disease","volume":"35","author":"Novak JS","year":"2021","unstructured":"Novak JS, Baksh SC, Fuchs E. Dietary interventions as regulators of stem cell behavior in homeostasis and disease. Genes Dev. 2021, 35:199-211. 10.1101\/gad.346973.120","journal-title":"Genes Dev"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.18632\/aging.101731","article-title":"Calorie restriction protects neural stem cells from age-related deficits in the subventricular zone","volume":"11","author":"Apple DM","year":"2019","unstructured":"Apple DM, Mahesula S, Fonseca RS, Zhu C, Kokovay E. Calorie restriction protects neural stem cells from age-related deficits in the subventricular zone. Aging (Albany NY). 2019, 11:115-26. 10.18632\/aging.101731","journal-title":"Aging (Albany NY)"},{"key":"ref80","article-title":"Dopamine agonists","author":"Choi J","year":"2023","unstructured":"Choi J, Horner KA. Dopamine agonists. StatPearls. StatPearls Publishing, Treasure Island, FL; 2023."},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.3233\/JPD-240272","article-title":"Parkinson\u2019s disease drug therapies in the clinical trial pipeline: 2024 update","volume":"14","author":"McFarthing K","year":"2024","unstructured":"McFarthing K, Buff S, Rafaloff G, et al.. Parkinson\u2019s disease drug therapies in the clinical trial pipeline: 2024 update. J Parkinsons Dis. 2024, 14:899-912. 10.3233\/JPD-240272","journal-title":"J Parkinsons Dis"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/430364-potential-synergistic-roles-of-ketogenic-diet-and-stem-cell-therapy-in-parkinsons-disease-a-narrative-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T21:57:35Z","timestamp":1770674255000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/430364-potential-synergistic-roles-of-ketogenic-diet-and-stem-cell-therapy-in-parkinsons-disease-a-narrative-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,9]]},"references-count":81,"URL":"https:\/\/doi.org\/10.7759\/cureus.103304","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2,9]]}}}